Varda Shoshan-Barmatz

This inventor holds 20 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Cancer Therapeutics. Top assignees: The National Institute for Biotechnology in the Negev Ltd., Ben-Gurion University of the Negev Research and Development Authority. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Varda Shoshan-Barmatz. Retrieved from https://idiyas.com/inventor/varda-shoshan-barmatz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 16)

Average Co-Inventor Count = 1.5

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

15 out of 33

The National Institute for Biotechnology in the Negev Ltd.

patents

10 out of 365

Ben-Gurion University of the Negev Research and Development Authority

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

VDAC1

Cancer

Biomarkers

Inflammatory Bowel Diseases

Apoptosis

Peptide Analogues

Tumorigenicity

CNS Disorders

Piperazine Derivatives

SMAC/Diablo Inhibitors

Mitochondria Dysfunction

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655433 - VDAC1 SILENCING MOLECULES AND USE THEREOF (2026-06-16),

2. 12544421 - VDAC INHIBITORS FOR TREATING INFLAMMATORY BOWEL DISEASES (2026-02-10),

3. 11976280 - SMAC/Diablo inhibitors useful for treating cancer (2024-05-07),

4. 11634465 - Analogues of VDAC1-derived peptides (2023-04-25),

5. 11555192 - SMAC/Diablo inhibitors useful for treating cancer (2023-01-17),

6. 11472777 - Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction (2022-10-18),

7. 11408887 - Biomarkers for diagnosis of lung cancer (2022-08-09),

8. 11286533 - Biomarkers of chronic lymphocytic leukemia and use thereof (2022-03-29),

9. 11174484 - Means and methods for reducing tumorigenicity of cancer stem cells (2021-11-16),

10. 10946013 - Methods for treating central nervous system disorders using vdac inhibitors (2021-03-16),

11. 10829530 - Analogues of VDAC1-derived peptides (2020-11-10),

12. 10787423 - Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction (2020-09-29),

13. 10508091 - Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction (2019-12-17),

14. 10434099 - Methods for treating central nervous system disorders using VDAC inhibitors (2019-10-08),

15. 10385104 - Analogues of VDAC1-derived peptides (2019-08-20),

Title: Varda Shoshan-Barmatz: Innovator in Cancer Treatment and Therapeutic Peptides

Introduction

Varda Shoshan-Barmatz, hailing from Omer, Israel, is an esteemed inventor and researcher with a remarkable portfolio of 18 patents. Her contributions primarily focus on groundbreaking methods and compositions for cancer treatment, targeting specific cellular mechanisms that play a crucial role in disease progression.

Latest Patents

Among her notable patents, Shoshan-Barmatz has developed innovative solutions such as SMAC/Diablo inhibitors useful for treating cancer. This patent outlines the development of compositions and methods aimed at inhibiting the expression and activity of the SMAC/Diablo protein. The inhibiting agents include RNA interference molecules that silence the SMAC/Diablo expression and peptides designed to modulate its interactions within the cell nucleus and mitochondria. These advancements hold promise for treating cancers where SMAC/Diablo is overexpressed.

Another significant patent involves analogues of VDAC1-derived peptides. This invention focuses on peptides that exhibit improved pharmacokinetic characteristics compared to their native counterparts. These peptides are effective in disrupting cell energy production, inducing apoptosis, and selectively targeting cancerous cells. Additionally, they show potential in addressing symptoms of nonalcoholic fatty liver disease (NAFLD), particularly in reducing fat accumulation in liver cells.

Career Highlights

Shoshan-Barmatz has had a distinguished career, contributing to vital research at respected institutions. Notably, she has been affiliated with the National Institute for Biotechnology in the Negev Ltd. and the Ben-Gurion University of the Negev Research and Development Authority. Her work in these institutions has not only advanced scientific knowledge but has also fostered innovation in therapeutic applications.

Collaborations

Throughout her career, Shoshan-Barmatz has collaborated with esteemed colleagues, including Arie Lev Gruzman and Salah Abu-Hamad. These partnerships have enhanced her research endeavors and contributed to significant advancements in her field.

Conclusion

Varda Shoshan-Barmatz stands out as a pioneering inventor in the realm of cancer therapeutics. With her extensive patent portfolio and collaborations with leading researchers, she continues to make strides in developing innovative solutions for combating cancer and related diseases. Her work exemplifies the spirit of innovation that drives progress in the scientific community.

Profile summary based on public USPTO records.